In situ intraduct carcinoma of the breast: A long term follow-up study
โ Scribed by R. R. Millis; G. S. J. Thynne
- Publisher
- John Wiley and Sons
- Year
- 1975
- Tongue
- English
- Weight
- 538 KB
- Volume
- 62
- Category
- Article
- ISSN
- 0007-1323
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Bax and Bc12 are functionally antagonistic proteins which control apoptosis, whose expression in human tumours could be of prognostic value. We evaluated Bax and Bcl2 expression in 239 breast carcinomas (99 N0, 140 N1/2) with long term follow-up (median 79 months, range 11-140) in relation to clinic
## Abstract ## BACKGROUND Ductal carcinoma in situ (DCIS) represents 20% of newly diagnosed breast carcinoma cases. Historically, the incidence of axillary metastasis in DCIS has been small (1โ2%) and its significance has been debated. It is widely known that serial sections of lymph nodes coupled
Ninety-eight women with lobular carcinoma in situ (LICS) of the breast were identified over a 16-year period. Consecutive slide review of all breast material over a 12-year period identified 25 women with LCIS o n biopsy who.did not undergo mastectomy. Only 1 woman (4%) in a complete followup averag
## BACKGROUND. Although in recent years there has been a dramatic increase in both the incidence of ductal carcinoma in situ (DCIS) and breast-conserving therapy for patients who have this disease, the optimal treatment for these patients remains controversial. Most data regarding outcomes have co